Treatment of ichthyosis and hypernatremia in a patient with Netherton syndrome with a SPINK5 c.153delT mutation using kallikrein inhibiting ointment

Int J Dermatol. 2017 Jan;56(1):106-108. doi: 10.1111/ijd.13248. Epub 2016 Feb 17.

Authors

Necip Ozan Tiryakioğlu¹, Zerrin Önal², Seha K Saygili³, Hasan Önal⁴, Nagehan Ersoy Tunali¹

Affiliations

¹ Department of Molecular Biology and Genetics, Haliç University, Istanbul, Turkey.
² Department of Pediatric Gastroenterology, T.R. Ministry of Health Bakırköy Sadi Konuk Training and Research Hospital, Istanbul, Turkey.
³ Department of Pediatrics, Istanbul Medical Faculty, Istanbul University, Istanbul, Turkey.
⁴ Department of Pediatric Endocrinology and Metabolism, Kanuni Sultan Süleyman Training and Research Hospital, Istanbul, Turkey.

PMID: 26889743
DOI: 10.1111/ijd.13248

No abstract available

Publication types

Case Reports

MeSH terms

Base Sequence
Dermatologic Agents / therapeutic use
Drug Combinations
Humans
Hypernatremia / drug therapy*
Hypernatremia / etiology
Ichthyosis / drug therapy*
Infant, Newborn
Kallikreins / antagonists & inhibitors
Netherton Syndrome / complications
Netherton Syndrome / drug therapy*
Netherton Syndrome / genetics
Ointments / therapeutic use
Proteinase Inhibitory Proteins, Secretory / genetics
Sequence Deletion*
Serine Peptidase Inhibitor Kazal-Type 5
Sodium Bicarbonate / therapeutic use*
Zinc Oxide / therapeutic use*

Substances

Dermatologic Agents
Drug Combinations
Ointments
Proteinase Inhibitory Proteins, Secretory
SPINK5 protein, human
Serine Peptidase Inhibitor Kazal-Type 5
Sodium Bicarbonate
Kallikreins
Zinc Oxide